Table 1 Compliance with QLQ-C30assessments

From: Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)

Time points

 

Forms expected

Forms received

Percentage

Difference P -value

Baseline

 

358

346

96.6

0.225

 

TPF

177

169

95.5

 
 

PF

181

177

97.8

 

End of cycle 2

 

328

282

86.0

0.340

 

TPF

164

144

87.8

 
 

PF

164

138

84.2

 

End of cycle 4

 

255

193

75.7

0.545

 

TPF

136

105

77.2

 
 

PF

119

88

74.0

 

At 6 months after RTa

 

198

108

54.5

0.794

 

TPF

112

62

55.4

 
 

PF

86

46

53.5

 

At 9 months after RTa

 

170

76

44.7

0.443

 

TPF

95

40

42.1

 
 

PF

75

36

48.0

 
  1. Abbreviations: QLQ-C30=Quality of Life Questionnaire C30; TPF=docetaxel, cisplatin, and 5-fluorouracil regimen; PF=cisplatin and 5-fluorouracil regimen; RT=radiotherapy.
  2. a 6 months and 9 months after the end of radiotherapy.
Back to article page